- Home
- BEAM
as 01-21-2025 3:32pm EST
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 1.9B | IPO Year: | 2020 |
| Target Price: | $47.67 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $20.84 - $49.50 | Next Earning Date: | 02-25-2025 |
| Revenue: | $349,643,000 | Revenue Growth: | 328.73% |
| Revenue Growth (this year): | -86.05% | Revenue Growth (next year): | 14.08% |
Stock Insider Trading Activity of Beam Therapeutics Inc. (BEAM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Bellon Christine | BEAM | Chief Legal Officer | Jan 2 '25 | Sell | $24.68 | 1,241 | $30,627.88 | 102,968 | |
| Cavanagh Bethany J | BEAM | SVP, Finance and Treasurer | Jan 2 '25 | Sell | $24.68 | 1,117 | $27,567.56 | 43,814 | |
| Ciaramella Giuseppe | BEAM | President | Nov 6 '24 | Sell | $26.36 | 51,110 | $1,347,050.05 | 109,150 |
Latest Beam Therapeutics Inc. News
BEAM Breaking Stock News: Dive into BEAM Ticker-Specific Updates for Smart Investing
Investor's Business Daily
9 days ago
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Zacks
9 days ago
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now?
GlobeNewswire
9 days ago
Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
Insider Monkey
23 days ago
Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In?
Insider Monkey
24 days ago
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?
Zacks
a month ago
5 Biotech Breakthrough Stocks to Watch in 2025
GlobeNewswire
a month ago
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Insider Monkey
a month ago
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers
Compare BEAM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BEAM Beam Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.